Return to Transcripts main page

First Move with Julia Chatterley

Trump Fires Official who Disputed his Election Fraud Claims; Pfizer- BioNTech Vaccine 95 Percent Effective with No Safety Concerns; Boeing 737 MAX Jets Can Fly Once More. Aired 9-10a ET

Aired November 18, 2020 - 09:00   ET

THIS IS A RUSH TRANSCRIPT. THIS COPY MAY NOT BE IN ITS FINAL FORM AND MAY BE UPDATED.

[09:00:47]

JULIA CHATTERLEY, CNN BUSINESS ANCHOR, FIRST MOVE: Live from New York, I'm Julia Chatterley. His FIRST MOVE and here is your need know.

You're fired. President Trump's sacks a senior official who said the 2020 election was secure.

Safety success. Pfizer ready to seek vaccine approval within days.

And cleared for takeoff. Twenty months later, Boeing 737 MAX jets can fly once more.

It's Wednesday. Let's make a move.

A warm welcome to you to FIRST MOVE. Once again, we begin the show today with the global health crisis like none other and a medical response that's

unparalleled in modern times, too.

Breaking news this morning. Pfizer saying the newest data that they have, show its vaccine now has a 95 percent efficacy rate and that they say it's

also passing some key safety milestones. Pfizer hopes to apply for Emergency Use Authorization to begin vaccinations in late December of this

year. Phenomenal news.

But of course, it doesn't help the near term COVID reality which remains unfortunately pretty bleak. In the United States, nearly 77,000 people

remain hospitalized. Both Russia and Poland reporting record numbers of lives lost to COVID.

Today, France has now also surpassed two million COVID cases. Japan meanwhile reporting its third biggest daily jump in new cases, too.

Weighing up the economic impact of all of this versus good vaccine news equals choppiness, volatility for stocks and for global markets, especially

as hopes for further financial support, at least here in the United States from U.S. Congress of fading once more.

Just take a look at the Japanese Nikkei. It closed lower for the first time this week. That despite encouraging export numbers close to pre-pandemic

levels. In fact, in the United States, the Dow and the S&P futures are retracing some of it yesterday's losses. In fact, actually we've turned as

you can see, and we are now at some four tenths of a percent higher premarket for the Dow helped along by Boeing, the 737 Max jets as I

mentioned, finally getting approval to fly again this morning after being grounded for some 20 months.

Now of course, we just need to get more people flying again. But tackling the pandemic, sadly, not the government's top priority at this moment.

Let's get to the drivers because we will begin once more in Washington where instead of concession, we see more signs of aggression. Donald Trump

firing the man in charge of election cybersecurity, Christopher Krebs, a top Director at Homeland Security for publicly rejecting one of the

President's main claims about election fraud.

Joe John's in D.C. for us. Joe, great to have you on the show, as always. The critics will say, look, this is the President once again, firing

someone who disagrees with his point of view, suppose that the President will perhaps be arguing this morning, is he covering something up? Is there

any evidence that this election wasn't secure? Or that there is some degree of fraud out there? Do we have any evidence?

JOE JOHNS, CNN SENIOR WASHINGTON CORRESPONDENT: No evidence, quite frankly. And the more you talk to elections officials around the country,

the more it becomes clear that what the evidence points to is that Chris Krebs, the cybersecurity expert who was fired was accurate when he said the

2020 election was the most secure election in American history.

Of course, the President begs to differ and that's why he says he got rid of Chris Krebs. Now, of course, it's an unpopular decision in many places

up on Capitol Hill, a number of Republicans have already said they disagree with the firing or at the very least, praised Krebs for what he has been

doing in that role at Homeland Security.

But the administration, including the White House Press Secretary, Kayleigh McEnany was out here on the driveway just a little while ago. She said,

Krebs, of course, and the President disagree. The President, obviously is the boss.

The President also in his position, unable to fire the President, the suggestion from Ms. McEnany is that there may have been some type of

political motivation or that Krebs had some type of a grudge against the President, not clear at all that that's true.

He is a highly regarded cybersecurity expert. He comes from Microsoft and has been in that position for quite a while.

[09:05:43]

CHATTERLEY: Joe, what are Republicans saying behind the scenes as they watch what's happening with the White House? With the firings? This is

clearly as we discussed over the past few days, not the first firing that we've seen of those around the President. What are they saying? If not, on

the surface, behind the scenes?

JOHNS: Well, right. It looks like an old-fashioned, authoritarian purge, quite frankly, coming at the end of an administration after an election.

Nonetheless, some Republicans up on Capitol Hill, powerful senators, including senators from states that the President won in the last election,

these are Republican senators are disagreeing with the President in one degree or another.

Most notably, I think, Ben Sasse, the Republican senator from Nebraska, who is known for his candor and speaking his mind, saying flatly, he did not

think that this man ought to have been fired. Others, simply praising Krebs for his work at Homeland Security -- Julia.

CHATTERLEY: This is very worrying. Joe Johns, thank you so much for that.

All right, on the Pfizer-BioNTech coronavirus vaccine. It is now 95 percent effective according to updated interim data from the pharmaceutical giant.

The CEO of Pfizer also confirming that they've got enough safety data now to ask the U.S. Food and Drug Administration, the F.D.A. for Emergency Use

Authorization.

Elizabeth Cohen joins me now. Elizabeth, two sets of great news, it seems coming from Pfizer and that BioNTech vaccine this morning. Walk us through

what more we know.

ELIZABETH COHEN, CNN SENIOR MEDICAL CORRESPONDENT: Sure, it's not just good news, because it shows that it's 95 percent effective, and it also

shows that it is generally safe. There were no serious side effects.

But this is also good news, Julia, just because it's more data. The more data the better. The more people who go through this study and who go

through the various stages of it, the better. The more sure we are that this data is right.

So let's take a look at what this data shows. When you take a look at this, the placebo group, so the 22-ish thousand people who were given a placebo,

just a shot of saline that does absolutely nothing, 162 of those people contracted COVID. Nobody gave them COVID. I mean, Pfizer didn't

intentionally give them COVID, they just caught COVID living their life, just like the rest of us. Nine of those 162 cases were severe.

Now, when you look at the vaccine group, the people who actually got Pfizer's vaccine, same amount of people, about 22,000, people got the

vaccine, only eight people got sick and only one of them severely.

Again, to be clear, Pfizer didn't give these people COVID. They just were out living their lives and in the course of living their lives, they caught

COVID. So, this is really important data. And again, the safety data shows that there were no serious side effects, things like you know, a sore arm,

things like that.

CHATTERLEY: Onwards towards trying to get F.D.A. approval, what do we know potentially about the timing of even setting up the meeting, and then

discussing with the F.D.A. what they've got here?

COHEN: So Julia, not to get too weedy and bureaucratic and nerdy on you, but I am going to do just that now.

CHATTERLEY: No, please do that. We like to --

COHEN: So, the F.D.A. in order to give the green light to this or not, they have to have a meeting of their Advisory Committee, and that is

outside experts. Those are people who have nothing to do with Pfizer, nothing to do with Moderna which is the other company that's about to apply

to the F.D.A. And so those outside experts have to meet and have to talk to the F.D.A. and all of this is very public and transparent.

That meeting has been set. That meeting is going to be, or at least, they've put aside three days for it according to a source that talked to

us. And that's December 8th, 9th and 10th.

The thinking is just sort of based on history, that at the end of the day on the 10th, the F.D.A. will either give a green or a red light. Now, once

the F.D.A. let's say they do give a green light and I think that's what's expected, then a committee at the C.D.C. needs to do its consideration as

well.

But the fact that they've already asked the folks on this F.D.A. Advisory Committee, hey, guys. Hold these days. Don't see patients. Don't do some

other work. We want you for these three days. That is very telling.

CHATTERLEY: Yes. Absolutely. And of course, as hopeful and as optimistic as we are and desperate, quite frankly to get this vaccine approved and

people being vaccinated, it doesn't help with the rising caseloads that we're seeing in America at this moment, the rising hospitalizations, both

at this moment, Elizabeth, at record levels.

[09:10:12]

COHEN: That's right. And I'm glad that you mentioned that because I think sometimes people think, oh, there's a vaccine, I don't have to worry about

anything else.

You do have to worry about something else. In the United States, many, many people, a good chunk of the country isn't even going to be able to start

getting the vaccine until the spring. It will take months and months to come even close to building anything that looks like herd immunity.

We are still going to have to wear masks. We are still going to have to do social distancing.

As you noted, these cases are basically rising out of control. We don't hear anything, really from the Trump administration about trying to get

this under control. It's just kind of let her rip.

And so what we're seeing is cases that are just going up, up, up. Hospitalizations that are going up, up, up; and deaths that are going up,

up, up.

CHATTERLEY: Yes, just have got to take care of yourselves and each other. Follow the precautions and keep doing it.

COHEN: Right.

CHATTERLEY: Elizabeth Cohen, thank you so much for that.

COHEN: Thanks.

CHATTERLEY: Across the Atlantic, in Europe, France, has become the first European nation to top two million cases. In Germany, thousands of

protesters holding an anti-corona measures demonstration in Berlin. The states of South Australia, shutting down for six days to curb the spread of

the virus, to South Korea where also, they are reporting more than 300 new infections today. That's the biggest daily jump since August.

And in Japan, reporting nearly 1,700 new cases. That's the country's third highest daily jump since the pandemic began.

Selina Wang is live in Tokyo looking at the details. Selina, just took us through the numbers here and how authorities are responding.

SELINA WANG, CNN CORRESPONDENT: Well, Julia, actually here in Tokyo, they reported 493 new infections on Wednesday. That's actually the highest daily

count since the pandemic started.

According to local news reports, Tokyo may be raising the COVID alert to the highest level and may ask businesses to close early. In other parts of

Japan, they have also been dealing with a surge in cases. Osaka has asked people not to leave, not to go out with more than five people. In other

parts like Sapporo, they've asked people to refrain from going out.

Now, what's interesting here is that Japan actually has never implemented a strict lockdown because the government doesn't have the legal means to

enforce one. But despite that, despite the relatively relaxed restrictions compared to the rest of East Asia, Japan has so far avoided an explosion of

cases. Total deaths is less than 1,900, and total infections are just over 120,000.

Experts do credit that to generally this culture of mask wearing, generally people adhering to those government guidelines. But I've spoken to many

infectious disease experts who are critical of what they see as the Japanese government's focus on boosting the economy, on encouraging

domestic tourism with these subsidies.

And they say, we are in this third wave that could get even worse in these winter months.

CHATTERLEY: Yes, every nation struggling to find a balance between supporting the economy and economic activity and curtailing and controlling

the virus.

Selina Wang, thank you so much for that update there.

Now, 2020 already been called at the worst ever year for aviation. It's especially true for Boeing amid the continued grounding of its bestselling

jet, the 737 MAX.

Well, at long last, the plane has F.A.A. -- that's the U.S. regulatory approval -- to fly once more. Richard Quest has all the details. Richard,

great to have you with us.

Is this the F.A.A. now saying what we saw in those two devastating crashes cannot happen again? Is that the message today?

RICHARD QUEST, CNN BUSINESS ANCHOR, QUEST MEANS BUSINESS: It most certainly is. And what the F.A.A. is saying clearly is that yes, the plane

now has a stamp of approval to fly. But that doesn't mean to say it will fly again tomorrow, or today or even the day after because the airlines now

have to go through and implement the changes the F.A.A. has required.

First of all, software enhancements, so the MCAS computer system doesn't do what it did in Lionair or Ethiopian and push the nose of the plane down.

So, you've got software enhancements. Secondly, you've got training for pilots. Steve Dickson, the F.A.A. administrator has taken the new training

plan and actually gone through it. He is a pilot, but now airlines have to put their own pilots through that training program.

And finally, the hundreds of 737 MAXes that are out there have to be readied to fly again. They've been in storage for over a year. It could

take several weeks to get each of those planes fit to go back in the air with passengers.

Just basic things like oil, engines, cleaning, making sure no dust has gone into places.

CHATTERLEY: It's quite fascinating. So, Richard, do you think we see one of these jets back up in the skies before we get to the end of the year as

a result and obviously, they are coming back at a time when we've seen the industry devastated by COVID.

I just wonder whether the quarantine, the health and safety fears perhaps overwhelm the fears that you and I talked about in the beginning of people

just simply being willing to get on this plane again and trusting it.

[09:15:19]

QUEST: I think there were two or three undercurrents there. The first, could they get them by the end of the year? Possible, but doubtful. There

is a lot of training that has to take place, a lot of software changes, and those planes do have to be readied. And that could take several weeks.

It's not -- it's possible, but I would say not likely. And anyway, do they need the planes is the second point, you were saying, Julia. Do they need

the planes at the moment? Not really. No airline wants to take on massive numbers of new planes. They can barely fly -- well, they can't fly the ones

they've got with passengers.

However, these new planes are much more fuel efficient. And in an era where you're looking at costs, you're certainly going to want to introduce them

to the fleet.

The last point, you know, it's a really important, Julia, that will passengers want to fly? But I'm sorry, I'm skeptical. Some might say

cynical, I believe within a short order, no passenger is going to seriously be asking, Is this a 737 MAX?

CHATTERLEY: Oh, I will. But you're right. That's just anecdotal. Richard Quest, thank you so much for that.

QUEST: Thank you.

CHATTERLEY: All right. Let me bring you up to speed now with some of the other stories making headlines around the world. Residents of Central

America are wading through a fresh round of wreckage.

Iota struck in Nicaragua on Tuesday as a Category Four Hurricane, just 24 kilometers from where another Category Four Storm hit around two weeks ago.

Authorities say, nearly all of Nicaragua's Caribbean Coast is without electricity.

The Trump administration has announced it will withdraw thousands of U.S. troops from Iraq and Afghanistan. The change will happen just days before

Joe Biden is sworn in as President and will leave around 2,500 troops in each country.

Acting Defense Secretary Christopher Miller said the plans do not reflect a U.S. policy change. But the decision was strongly opposed by former Defense

Secretary Mark Esper, who was fired by the President last week.

Coming up after the break, the CEO of Emirates on the inevitable the airline posing its first loss in more than 30 years.

And vaccine breakthroughs coming at a breathtaking pace, the risk of getting it wrong. A sober warning on FIRST MOVE, coming up. Stay with us.

(COMMERCIAL BREAK)

CHATTERLEY: Welcome back to FIRST MOVE. U.S. markets remain on track for some early session gains. This, after the Dow the S&P pulled back from all-

time highs on Tuesday. Now, you can see the NASDAQ futures slipping a little bit as I watch.

News from Pfizer that its COVID vaccine is 95 percent effective in their latest interim data and safe for seniors is helping lift sentiment. Pfizer

shares up over two percent as you can see on the news premarket.

Retail is also in focus. Target, a big gainer, too. It is reporting double digit Q3 sales gains and huge growth in its curbside pickup activity and

home delivery services.

The Dow also getting a lift from component, Boeing. As we've been discussing with Richard this morning, it shares ups some seven percent

premarket. The U.S. says the 737 MAX can finally fly again.

But clearly, as Richard was saying a number of steps to go through first. The airline industry clearly getting excited by the latest update on

vaccine developments. The President of Emirates, the Middle East's largest carrier is forecasting a return to profitability in the first half of 2022.

Emirates recently posted its first loss in more than three decades. John Defterios joins us live from Abu Dhabi, who has been speaking to Emirates.

John, great to have you with us. Clearly, there's a good time coming, but it could just be a good time coming. It's going to take a while for people

to get vaccinated and get people back in the skies. And that's clear, I think.

JOHN DEFTERIOS, CNN BUSINESS EMERGING MARKETS EDITOR: Yes, I think you're right, Julia. Sir Tim Clark was suggesting -- the President of Emirates

Airline -- you have to look at six to nine months to get into the market. He bangs on about the same thing that we've talked about, very vital to get

it into the developing world, particularly very populated countries like India, and that's stretching down to Africa.

But think about the struggle for Emirates. It's gone from $5 billion from peak to trough in a year. Not unusual, because that's happening in the

United States, Europe, and also the Asian carriers. But he is excited about what we see from Pfizer and Moderna and the efficacy of those tests.

And also keep in mind here that Russia and China are experimenting with their vaccines as well. So I asked him, collectively, could this be the

silver bullet for the industry, or not? Here is Sir Tim Clark.

(BEGIN VIDEOTAPE)

TIM CLARK, PRESIDENT, EMIRATES: I can see no other way out of this pandemic and they have to be the silver bullet. We've got track and trace.

We've got lockdowns. We've got all sorts of protocols, social distancing, et cetera, et cetera.

But still, in the West, in America, in Europe, it is rampant, even under nine months of all sorts of protocols to try and mitigate the risk of

infection. So for me, if it is as it is, it's absolutely vital that we roll these out at scale, at speed, and get them administered as quickly as

possible, only then will we get ourselves through this.

DEFTERIOS: So, let's talk it through what's realistic in terms of global distribution. You have the hub here, set and ready to go. We're looking at

the second half of 2021, or the second quarter of 2021 on a global scale.

CLARK: No, I think if they do come out, and we have got the logistics of the supply chain sorted, of course, in Europe and America, they can be road

transport, they can be the integrators, FedEx, UPS, can fly them around, and do all that.

But once you're talking about this transoceanic and remote continents from the actual production source of the pharmaceutical side of things, you need

to get all of this sorted out. And it is that that in tandem with the scaling up of production, in tandem with the scaling up of the supply

chain, whether it be ground and air, it will take time, six to nine months, which is why I believe we will see during the course of 21 all of this

getting into place in the last quarter.

And as that happens, you will see demand for air travel, grow, I believe at pace.

DEFTERIOS: At pace, back to normal, perhaps by the first quarter of 2022 is what you're suggesting.

CLARK: I would think that during the first quarter, first half, the two -- the first six months of '22, you'll see a lot of this coming back.

So I'm expecting that, maybe I'm over optimistic, but in all the years I've been in this business, and led a business which is global in its reach, and

seeing how countries have responded to various crises, time and time again, even with the big crises, the big disruptions to the global economy, it has

bounced back and that's what I'm expecting.

(END VIDEOTAPE)

[09:25:08]

CHATTERLEY: John, it is quite fascinating to hear just his sense of how long distribution of vaccine takes and the logistical issues which we've

been talking about on a daily basis on the show.

But how does that fit just in terms of the timing, as he was saying profitability, perhaps by 2022 amid the broader strategy here and they've

had a lot of the workforce go as well. And we're talking about a long way out, even today.

DEFTERIOS: Yes, indeed, Julia, but you have to think about the last nine months what they've gone through. You know, Emirates took this calculated

risk, as the Chairman was suggesting to reopen in May, and many were saying, well, that was premature, but Dubai needs to do so because tourism

and travel is so important to the economy there.

They worked very hard to build up an air corridor, Julia, and it happened with Heathrow in the last week. Sources at Emirates tell me, expect more to

come. So, they are looking to set the protocols.

And you know, they tested this vaccine distribution out of Dubai during the Ebola crisis between 2014 and 2016. In the end, it wasn't needed. But they

went through that trial and they think that they are well-positioned for South Asia and Africa. They already have the flight connections there and

they are running at 75 percent of the routes right now.

So as soon as they get the clearance here, they have the refrigeration and they are ready to go. And they think it gives them that kind of first mover

advantage to get back into profit in 2022.

He was extremely bearish, Julia, six months ago saying it could be 2023 or longer to get back to normal. So the vaccines are resonating well with Sir

Tim, who by the way, was going to retire and stayed on to get through the crisis for Emirates and did not get an end date right now.

CHATTERLEY: Yes, fascinating, though. He has brought forward those recovery plans by some two years as a result of what we're talking about

here. It is a game changer as everyone is saying, we just need to get to that point.

Jeff Defterios, thank you so much for that. Great to have you with us.

The market open is next. Stay with us.

(COMMERCIAL BREAK)

[09:30:07]

CHATTERLEY: Welcome back to FIRST MOVE and U.S. stocks are up and running this Wednesday. That's the opening bell over there at the New York Stock

Exchange and we've got a higher open for the Dow and the S&P 500 this morning, two tenths of one percent. And just looking at the big board

there.

Gains, not as strong as we were seeing premarket, but investors do applaud news from Pfizer this morning that their COVID vaccine has passed their

final safety reviews with a stunning 95 percent efficacy rate, still interim data though, let's be clear on that point.

Bitcoin in the meantime is blazing. The digital asset crossing 18,000 for the first time in almost three years today. That's less than 10 percent

away from record highs. But I have to say, fading hopes for new U.S. emergency aid remain a market concern.

Congressional Democrats have asked Senate Majority Leader McConnell to restart negotiations immediately, quote, "for the sake of the country."

Mitch McConnell says the Democrats' price tag is still too high. Watch that $2 trillion -- near $2 trillion gap.

Now, there are fast and furious developments in the vaccine race, as we've been describing throughout the show with Pfizer-BioNTech moving towards an

application for Emergency Use Authorization in the United States. The Food and Drug Administration, the F.D.A., says the vaccine makers following

Operation Warp Speed only need two months of follow up data from clinical trials to apply for that Emergency Use Authorization.

However, my next guest says that's not long enough and he'd like to see six months' worth of data. Dr. Marcus Schabacker is the President and CEO of

ECRI, Emergency Care Research Institute, an independent nonprofit for healthcare worldwide.

Dr. Schabacker, fantastic to have you on the show. We're clearly all emotional, I think about these vaccines. We're desperate to get a vaccine

and get back to normal, but just explain why you feel just waiting those few extra months is so important at this moment.

DR. MARCUS SCHABACKER, PRESIDENT AND CEO, EMERGENCY CARE RESEARCH INSTITUTE: Yes. Good morning, Julia. And first of all, thank you for

having me on. It's exciting time. I mean, there's a glimmer of hope, finally, at the end of a long, dark, 11 months, if I may say.

So clearly, we are very excited about these early signs of effectiveness both in the Pfizer as well as in the Moderna trial. But they are early

indications. They are not the final results. And the nature of clinical studies is that they are trying to represent the overall population and go

through very detailed statistical models.

And these statistical models only bear out when you let the trial run its course, including its follow up and we just believe that two months of

follow up is not enough.

CHATTERLEY: You know, a couple of things that you and I have spoken about of a -- is the inherent bias that you tend to get in early data just with

who is willing to sign up for the trials. I know this is sort of one concern for you, as you look across all of these different vaccine trials

that are going on at this moment.

The second thing is, particularly when it is a two-dose vaccine, how do you know how effective it is if you've only seen two months of data after the

vaccine, particularly when the technology, the science of some of these platforms like the mRNA, which is that the messenger RNA mechanism, the

platform for Moderna and for Pfizer has never even been used before?

These are logical concerns for me in both cases.

SCHABACKER: Absolutely. And, you know, you're right. These technologies have never been used in vaccines before. So we just don't know about their

long term effect. And by limiting the review data to two months, we just might miss longer term side effects or adverse events, which could be

severe, and we simply don't know.

The other point you made earlier is about the bias from a time perspective. Now, clinical trials are designed as that you look for volunteers, and we

compliment both Pfizer and Moderna for really trying to get a diverse group of patients from an age, from a gender perspective, people of color and so

on.

So they have done a good job in designing those, but typically what you see is that these groups are from a recruitment perspective happening later in

your trials because they are difficult to recruit.

So when you go with only two months data, you get a bias towards those early volunteers who signed up, and you typically might not have the same

risk profile because they are not as exposed and you know, just -- it's not a total science in this, but if you look at this, the total population in

the United States had about plus three percent of infection rate, right, 11 million out of 330 million.

[09:35:09]

SCHABACKER: In the Moderna trial, for example, we have only seen 0.6 percent of infected patients in the placebo trial. Now, again, that's not

an entirely fair comparison, because you do these statistical models to represent the overall population, but you need to give it time.

And the other aspect, you know, I wanted to talk about is the effectiveness over time. So, if you stop at two months, you might not see if somebody

gets infected from the vaccinated group later, like four months, five months, six months, and we need a vaccine, which is really effective at a

minimum of six months.

So if we stop early, we have that risk on missing the severe side effects, and missing if the vaccine is only active for a short period of time.

CHATTERLEY: Okay, so what you're saying here is side effects, again, because we've never used this platform for vaccines before could appear

within a six-month period, not just a two-month period. So you all raising safety concerns, even just with two months of data.

But I think the other critical point that you're mentioning here is we don't know how long the immunity that the system builds as a result of this

vaccine lasts. So we could once again lose that immunity within a short window and perhaps in the future need to have four vaccines, two shots

twice a year, for example. And you're saying that could be impracticable?

SCHABACKER: Well, that's impracticable, and most importantly, we would lose the trust of the population. So for example, if we send everybody go

and get vaccinated, we'll make a big deal out of it and then we find out that in the next fall, everybody who have been vaccinated in the spring is

going to get sick again. Then they're going to say, well, that obviously doesn't work, and we already have great skepticism around vaccine in this

country.

So that would not be helpful, it would set us back years, and we are saying just go a little slower, not a lot, just a little slower, four months, and

get the sufficient data, get more reliable data both from an effectiveness perspective, as well as from a side effect, adverse event perspective, and

use that time. Use that time to get your logistics in order.

I know there's different opinions about that. We have great concerns about the logistics. This is a massive operation when you're trying to vaccinate

millions and millions of people with two doses, which need to be refrigerated in case of the Pfizer vaccine, they need to be deep frozen in

minus 70. That causes logistical challenges.

So use the time, it's not wasted, and go faster after you know that the vaccine is effective and safe.

CHATTERLEY: Everything that you've said makes sense to me. Marcus, how likely is it that the F.D.A. decides to wait longer before it gives this

F.D.A. approval, because it feels like a very low probability event, and one of the other concerns that you and I have discussed is the trials end.

So there will be people watching this going, hey, look, just give the approval. Let the trials effectively continue and continue to collect the

data. But ethically, you can't do that. Can you?

So once you've given F.D.A. approval, that's it.

SCHABACKER: Right. So, once you have given this, and again, it's not a full approval, right? It's a shortened abbreviated process already. It's

called Emergency Use Authorization. And, you know, we are not opposed to that at all. Because, it usually takes over a year for those clinical trial

follow ups. So we are just saying, do six months instead of two.

But once you have given that approval, this Emergency Use Authorization, it's not an approval, that authorization, it becomes ethically very

difficult to withhold the vaccine from those who are in the studies or in the general population. Because imagine, you know, you are one of those who

might or might not have gotten the vaccine and you say, well, you've given emergency authorization, now you need to please un-blind everything, so I

know if I got it or not. Because if I didn't get it, I want to get it now.

And then we are losing this entire follow up, which is so critical, particularly for the long term side effects and for the long term

effectiveness. So we are just saying, just stick to what you designed it for, which is good. The trials are well designed. Give it the time it

needs.

CHATTERLEY: Yes, because people who got the placebo are going to act differently than they might have done if they thought that they'd got the

vaccine in the first place. Very quickly, because I'm running out of time, when this vaccine becomes available, Marcus, are you going to take it? Are

you going to recommend that your family take it or will you wait the six months just to see what happens even if other people are being given the

vaccine?

SCHABACKER: I stick to my guns here. I would not give it to my family. If it gets authorization within two months, I would see what the longer term

effects are and continue to behave like we all should which is wearing a mask, doing good hand hygiene and socially distance.

So, unfortunately, we are losing a lot here if we are not going for at least six months.

[09:40:19]

CHATTERLEY: Yes, I guess for most people, they won't get the vaccine for six months, because it's going to take some time to your point about

distribution, but not the point. Yes.

Dr. Schabacker, fantastic to have you on the show. Thank you so much for joining us. And thank you for the work that you're doing. From ECRI there.

SCHABACKER: Thank you, Julia.

CHATTERLEY: Thank you.

All right, after the break, from vaccines to the now. To testing, a technology that sits in the palm of your hand and results come within 15

minutes. Stay with FIRST MOVE. That's up next.

(COMMERCIAL BREAK)

CHATTERLEY: Welcome back to FIRST MOVE. The United States has recorded its deadliest day of the coronavirus pandemic in six months. Over the past

week, the country has averaged 155,000 cases per day as Sara Sidner reports.

(BEGIN VIDEOTAPE)

SARA SIDNER, CNN CORRESPONDENT (voice over): State and local leaders across the United States are grappling with the relentless spread of

coronavirus. The country reporting another 161,000 new coronavirus cases Tuesday and reporting the highest day of deaths since May.

GOV. LARRY HOGAN (R-MD): We are in a war right now and the virus is winning.

SIDNER (voice over): More than a dozen states are implementing new mitigation efforts and mask mandates over the past week, and some cities

and states have taken more drastic measures, such as issuing stay-at-home advisories or restricting nonessential businesses like restaurants and

gyms, including Michigan, where a three week pause in reopening goes into effect today. This month the state has seen its worst numbers since the

start of the pandemic.

And in Washington, Governor Jay Inslee reported it state saw more than 2,600 new cases Tuesday, the highest since the pandemic began.

Earlier, Inslee closing indoor dining services and limiting store capacity to 25 percent in response to the rising spread.

GOV. JAY INSLEE (D-WA): It is a scientific reality that if things do not change, this number will continue to skyrocket.

SIDNER (voice over): In Montana, Governor Steve Bullock announced a statewide mask mandate; and in St. Louis, it is closing restaurants and

bars to in-person dining and encouraging people to only leave home for essentials.

In Minnesota, cases are on the rise and local news reports a new measures are expected to be announced by Governor Tim Walz today.

In Kentucky, the Kentucky Governor also expected to announce new measures today according to local reports. This comes after the state saw 33 people

lose their lives to the virus, the highest number of deaths in a single day in that state.

DR. FRANCIS COLLINS, DIRECTOR, NATIONAL INSTITUTE OF HEALTH: At this point, we've got a few months before the vaccines come to the rescue. We

want to save as many lives as we can in that interval. And that's really up to all of us.

SIDNER (voice over): On the vaccine front, Pfizer says, it is ready to seek an Emergency Use Authorization for its version.

Rick Bright, who left the Trump administration earlier this year and now serves on President-elect Joe Biden's Coronavirus Advisory Board is

concerned about vaccine distribution.

RICK BRIGHT, MEMBER, PRESIDENT-ELECT BIDEN'S COVID ADVISORY BOARD: We've had very limited of any interaction with any of the companies that are

working on the pandemic response as well.

(END VIDEOTAPE)

CHATTERLEY: America not the only country working on vaccines, of course, China also pushing ahead with the development of their own vaccine. The

country is all too familiar with the challenges of containing the virus given how it first came out of Wuhan. Health experts say it's vital no

corners are cut as Ivan Watson reports.

(BEGIN VIDEOTAPE)

IVAN WATSON, CNN SENIOR INTERNATIONAL CORRESPONDENT: China is a big player in the global race to develop a coronavirus vaccine. As of now, Chinese

companies have five different experimental vaccines that have advanced to Phase 3 trials in different countries around the world.

The Chinese government has declared vaccine development a top priority.

ZHAO LIJIAN, SPOKESPERSON, CHINESE FOREIGN MINISTRY OF AFFAIRS (through translator): Chinese vaccine companies are making every effort to promote

vaccine research and development. Several vaccines have already entered Phase 3 clinical trials.

The Chinese government has also been actively supporting Chinese companies to cooperate with other countries in vaccine research and development.

WATSON: The company, Sinovac calls its vaccine candidate CoronaVac. It's being tested on volunteers in Brazil, Turkey and Indonesia. And though it's

still in the experimental phase, the Indonesian government announced plans to start administering millions of doses to citizens as early as next month

under Emergency Use Authorization.

The company Sinopharm has two vaccine candidates which are being tested in the Gulf, North Africa and South America. Among those who volunteered for a

Sinopharm experimental vaccine, the UAE's Foreign Minister and the Ruler of Dubai, who both tweeted about it.

A top executive at Sinopharm says some 350,000 people in China have already taken one of its experimental vaccines. CanSino Biologics experimental

vaccine was co-developed with the Academy of Military Medical Sciences, and it has been approved for use by the Chinese military.

It's also being tested in Russia, Pakistan and Mexico. The Mexican government says it has an agreement to purchase 35 million doses of

CanSino's product.

Finally, the government of Uzbekistan reportedly announced it will be conducting Phase 3 trials of an experimental vaccine developed by Anhui

Zhifei Longcom Biopharmaceutical. Some health experts are concerned about vaccines being widely distributed for emergency use before Phase 3 trials

are complete.

DR. PETER HOTEZ, DEAN OF THE SCHOOL OF TROPICAL MEDICINE, BAYLOR COLLEGE OF MEDICINE: This is the part that I worry about with both the Russian

vaccines and the China vaccines is the quality control and all of the assurance to know that these vaccines are being adequately tested for

safety and efficacy.

And unfortunately, we don't have a lot of information about that.

DR. LEANA WEN, CNN MEDICAL ANALYST: it really is important that we don't take shortcuts to the science. These protocols are there for reason. They

are there to protect people.

WATSON: That sentiment echoed this week by one of the authors of a study on Sinovac's vaccine candidate. "CoronaVac could be an attractive option,"

he wrote. "However, data from Phase 3 studies will be crucial before any recommendations can be made."

Ivan Watson, CNN, Hong Kong.

(END VIDEOTAPE)

CHATTERLEY: Fascinating. You're watching FIRST MOVE. More to come. Stay with us.

(COMMERCIAL BREAK)

CHATTERLEY: Welcome back to FIRST MOVE. It's a brand whose name evokes the sound of music itself: Steinway. The legendary piano maker who for more

than 160 years has given Maestros the chance to lead concertos and helped move audiences all around the world. Steinway is part of our 100 Club.

(BEGIN VIDEOTAPE)

RON LOSBY, CEO, STEINWAY AND SONS: Whether you're listening to it or whether you're playing it, what comes out of it is emotional. And it is

something that makes you feel you know very human.

UNIDENTIFIED MALE: Ron Losby has spent more than three decades of his career surrounded by pianos.

The story of Steinway and Sons began in Germany in 1836 when cabinet maker Henry Engelhard Steinway made his very first piano. It would take nearly

two decades before he would go on to start the company known today, in 1853 in New York City.

ROBERT BERGER, DIRECTOR OF CUSTOMER SATISFACTION, STEINWAY AND SONS: They wanted to build the piano by which all others would be judged.

UNIDENTIFIED MALE: In 1877, they began partnerships with universities.

BERGER: They very early worked to have relationships through the dealer network with various musical schools, conservatories, and because of that,

the name Steinway was there very early.

UNIDENTIFIED MALE: In a world of increasing automation, each instrument is still crafted by hand, even as the company embraces digital technology. And

in 2015, their Spirio System ushered in a keyless era for their pianos.

LOSBY: A piano traditionally has nothing digital, it was not at all involved in that world. Now, we are able to appeal to someone who never

thought about playing the piano, never wants to play the piano, but they can have the experience and reveal the beauty of a Steinway piano on their

own, without ever having to touch a note on it.

And that will expand the market and has expanded the market for our pianos throughout the world.

UNIDENTIFIED MALE: That new market has been critical during a year marked by a crippling health crisis that has left concert halls across the world

empty.

As the company closes in nearly 170 years in business, finding the harmony between adaptation and upholding tradition is what those here say will

drive the brand into the next century.

(END VIDEOTAPE)

CHATTERLEY: Amazing to see how they are created. All right, and finally the robots are calling the shots in a sports shop in Japan.

[VIDEO CLIP PLAYS]

[09:55:15]

CHATTERLEY: This electronic enforcer telling people to put masks on and to follow social distancing measures. It's the work of a Research Institute in

Kyoto promoting a society where people and robots co-exist.

Yes, I'm just looking at that. I've seen "Doctor Who." I know exactly how that ends.

That's it for the show. You've been watching FIRST MOVE. I'm Julia Chatterley. Stay safe.

Richard Quest is in the hot seat for me tomorrow. I'll see you on Monday next week. Stay safe, friends.

(COMMERCIAL BREAK)

[10:00:00]

END